Clinical Trial Update: Feasibility Study of CDDP + CPT-11 + PSK for Extensive-Stage Disease (ED) Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

This is a Phase 2 feasibility trial evaluating cisplatin (CDDP), irinotecan (CPT-11), and polysaccharide-K (PSK) for extensive-stage small cell lung cancer. The…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Irinotecan (Irinotecan)
• PSK (polysaccharide-K)

Snippet

Sponsor: University of Toyama | Conditions: Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN